David S. Wolpa Counsel

David concentrates his practice on securities, capital markets transactions, mergers and acquisitions and general corporate matters, representing issuers in a wide variety of industries, including healthcare and life sciences, manufacturing and technology, as well as investment banks acting as underwriters or placement agents.

David has experience counseling publicly traded clients on matters pertaining to securities law compliance, stock exchange listing standards and corporate governance issues. He also works closely with directors and senior management on a broad range of other legal matters, including corporate governance, fiduciary duties and stock exchange listing compliance issues.

David is dedicated to applying his experience and deep understanding of securities and corporate law to advance his client’s business goals and objectives.

Prior to joining McGuireWoods, David worked for a full-service law firm in Chicago, Illinois.

Experience

Representation of Teledyne Technologies, Inc. (NYSE: TDY), a leading provider of sophisticated electronic components, instruments and communications products, in its $8 billion acquisition of FLIR Systems, Inc. (Nasdaq: FLIR), a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications.

Representation of ThinkEquity, as representative of the several underwriters, in the $25 million initial public offering by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics.

Representation of Cleveland BioLabs, Inc. (Nasdaq: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs, in its merger with Cytocom Inc., a private a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary, multi receptor platform, or the AIMS platform, designed to rebalance the body’s immune system and restore homeostasis.

Representation of Stifel, Nicolaus & Company, as representative of several underwriters, in a $63 million initial public offering of common stock by Karat Packaging Inc. (Nasdaq: KRT), a rapidly-growing specialty distributor and select manufacturer of environmentally-friendly disposable foodservice products and related items. 

Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private of and sale of convertible promissory notes and warrants by Ordergroove, Inc., the operator of an e-commerce platform for retailers. 

Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private offering and sale of preferred stock by Cyprium Therapeutics, Inc.,  a clinical-stage biopharmaceutical company.   

Representation of National Securities Corp., acting as sole book-running manager, in connection with a public offering and sale of common stock by Super League Gaming, a company that brings live and digital e-sports entertainment experiences directly to competitive gamers. 

Representation of  B. Riley FBR, Inc. (formerly FBR Capital Markets & Co.) as placement agent in connection with the extension of its existing relationship with Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company.

Representation of Alliance Global Partners (AGP), a regional investment and advisory firm providing investment advisory and brokerage services to individuals and institutions, in connection with the launch of an at-the-market program in which AGP serves as placement agent to ProPhase Labs, Inc. (Nasdaq: PRPH), a manufacturing and marketing company with experience with OTC consumer healthcare products and dietary supplements.  

Representation of Pareteum Corporation (Nasdaq: TEUM), a global cloud communications platform company, in its issuance of $17.5 million in senior secured convertible notes, with warrants, to an institutional investor. 

Representation of a publicly traded innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs in its $3.175 million at-the-market registered direct offering of common stock.

Representation of ThinkEquity, as representative of the several underwriters, in the initial public offering by LMP Automotive Holdings Inc. (Nasdsq: LMPX), an e-commerce and facilities-based platform where users can buy, sell and rent new and used automobiles.

Representation of ThinkEquity, as sole book-running manager, in the $19.2 million follow-on equity offering by LMP Automotive Holdings Inc. (Nasdsq: LMPX), an e-commerce and facilities-based platform where users can buy, sell and rent new and used automobiles.

Representation of Speedway Motorsports, Inc. (NYSE:TRK), a leading marketer and promotor of motorsports entertainment, in its public company “going private” 2-step tender offer and merger transaction with Sonic Financial Corporation and O. Bruton Smith and his family, in a transaction valued at over $265 million.

Representation of JMP Securities, initial purchaser and placement agent, in connection with a concurrent $30 million Rule 144A convertible debt and $9.5 million private placement (PIPE) of Class B Common Stock of RumbleOn, Inc. (Nasdaq: RMBL).

Representation of National Securities Corp., lead book-running manager, and Craig-Hallum Capital Group, joint book-running manager, in a $7.5 million underwritten public offering of Class B Common Stock of RumbleOn, Inc. (Nasdaq: RMBL).

Representation of National Securities Corp. and Craig-Hallum Capital Group as placement agents in connection with a $21.6 million private placement (PIPE) of Class B common stock by RumbleOn, Inc. (Nasdaq: RMBL).

Representation of National Securities Corp. as underwriter in connection with an underwritten public offering of Class B Common Stock by RumbleOn Inc. (Nasdaq: RMBL).

Representation as underwriters’ counsel of National Securities Corp., as representative of the underwriting syndicate, in connection with a follow-on public offering of common stock by Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immune-oncology biopharmaceutical company.

  • Loyola University Chicago School of Law, JD, magna cum laude, Dean’s List, Senior Member, Loyola University Chicago Law Journal, 2008
  • University of Illinois at Urbana-Champaign, BA, Political Science and History, summa cum laude, Phi Beta Kappa, 2004

Member, American Bar Association

  • Illinois
  • North Carolina
Back to top